|
Post by mnkdfann on Jun 12, 2016 0:39:18 GMT -5
As someone else mentioned it does seem odd that the company name is missing. That does not seem so odd to me. They want to promote the drug, not the company. I've seen many drug adverts where the name of the company is not mentioned, or mentioned only in small print in passing. Just as a for instance, check out www.advil.com
|
|
|
Post by ilovekauai on Jun 12, 2016 0:46:21 GMT -5
Not impressed at all with booth. I disagree. Mnkd has 1 product and they don't have much money. Being there with a booth at all is good. I'm not sure how much you can tell by looking at a few twitter photos.
|
|
|
Post by ilovekauai on Jun 12, 2016 0:49:26 GMT -5
Q: What did you expect? The Taj Mahal? Let the staff make contact, imprint their leads, and get the sales force out there next month to follow-up on what they pull in. That's what a trade show is all about. C'mon MNKD, keep at it and do us good!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 12, 2016 6:08:01 GMT -5
What's done is done, and I'm not even going to comment of the booth because I'm just happy they are there, and presented us with some great news. The announcement I'm sure brought them plenty of attention, whether physically at the booth, or people making a mental note to look into them.
|
|
|
Post by rockstarrick on Jun 12, 2016 8:59:27 GMT -5
I disagree. Mnkd has 1 product and they don't have much money. Being there with a booth at all is good. I'm not sure how much you can tell by looking at a few twitter photos. A lot, actually. I'll censor myself out of any additional comment on it. I hope the show is a success for MNKD, in any case. That's all that matters. I can see where you both are right !!! that will be my politicrally correct statement of the day. personally I think the booth, big or small, like it or not, still paints a very clear picture that mnkd is not going to just roll over and give up !!! Mnkd has been very busy assembling and training a marketing team, all while preparing for this presence at the ADA. The booth and slogan, in my opinion, represent the beginning of the re-birth of afrezza !! Mike Castagna is about release these newly trained sales representatives, we are about to see how well Afrezza sells when people are actually trying to sell it !!! Very exciting for me, I have always believed afrezza will become at least one of the top selling mealtime insulin products, I hope I'm right. Good Luck Everybody
|
|
|
Post by nylefty on Jun 12, 2016 9:05:43 GMT -5
As someone else mentioned it does seem odd that the company name is missing. That does not seem so odd to me. They want to promote the drug, not the company. I've seen many drug adverts where the name of the company is not mentioned, or mentioned only in small print in passing. Just as a for instance, check out www.advil.comAbsolutely. Too many of us put too much emphasis on the day-to-day stock price of MannKind when the focus should be on selling Afrezza. When that happens the stock price will follow.
|
|
|
Post by bradleysbest on Jun 12, 2016 9:10:04 GMT -5
Agree, when scripts start rising everything will change including the stock price.
|
|
|
Post by agedhippie on Jun 12, 2016 9:12:48 GMT -5
That does not seem so odd to me. They want to promote the drug, not the company. I've seen many drug adverts where the name of the company is not mentioned, or mentioned only in small print in passing. Just as a for instance, check out www.advil.comAbsolutely. Too many of us put too much emphasis on the day-to-day stock price of MannKind when the focus should be on selling Afrezza. When that happens the stock price will follow. Agreed. This is specifically a diabetes conference and the diabetes product is Afrezza. That's where the focus belongs, not on the company.
|
|
|
Post by capnbob on Jun 12, 2016 10:13:53 GMT -5
The booth does appear a little bland. There is a lot of white space on the walls. In future, they could put some pictures and profiles of happy Afrezza users in some of the empty space, telling their Afrezza experiences in their own words. That would nicely fit the "Let's Talk About Afrezza" story-line. Exactly. Would it hurt to have just a little "eye candy"? Although terribly sexist and objectifying women, a large photo of, say, Miley Cyrus taking a suggestive "inhalation" on a dreamboat would probably have made a much more lasting impression on the generally male population. Also, I think what appears to be a video about "bluhale technology" could be a mistake. It might suggest to viewers that some sort of special training is required.
|
|
|
Post by mnkdfann on Jun 12, 2016 10:19:10 GMT -5
The booth does appear a little bland. There is a lot of white space on the walls. In future, they could put some pictures and profiles of happy Afrezza users in some of the empty space, telling their Afrezza experiences in their own words. That would nicely fit the "Let's Talk About Afrezza" story-line. Exactly. Would it hurt to have just a little "eye candy"? Although terribly sexist and objectifying women, a large photo of, say, Miley Cyrus taking a suggestive "inhalation" on a dreamboat would probably have made a much more lasting impression on the generally male population. I wasn't talking about "eye candy" ... just regular happy Afrezza users telling their stories. Something very simple, cheap, and effective. Besides which, they don't have the money to get Miley Cyrus or any like celebrity involved in the marketing.
|
|
|
Post by mydogskip on Jun 12, 2016 10:46:45 GMT -5
Exactly. Would it hurt to have just a little "eye candy"? Although terribly sexist and objectifying women, a large photo of, say, Miley Cyrus taking a suggestive "inhalation" on a dreamboat would probably have made a much more lasting impression on the generally male population. I wasn't talking about "eye candy" ... just regular happy Afrezza users telling their stories. Something very simple, cheap, and effective. Besides which, they don't have the money to get Miley Cyrus or any like celebrity involved in the marketing. The FDA has strict guidelines of what you can proclaim and what you can't. Doing what you have suggested would have run afoul of those guidelines. Mannkind can't parade their users around detailing their experience. The company would have to run a P4 clinical trial to prove lower A1c or anything else we have witnessed from users. Obviously, that takes moneyt hat Mannkind doesn't currently have.
|
|
|
Post by mydogskip on Jun 12, 2016 10:50:23 GMT -5
Agree, when scripts start rising everything will change including the stock price. While I believe scripts will rise, what if they only hit the highest mark while under Sanofi? The biggest question is how effective will the new sales team be in getting endos to prescribe? And remember, it appears the target as of right now is T1s and not T2s unless those endos seeing T2s change their protocol and start their T2s on Afrezza instead of metformin.
|
|
|
Post by kbrion77 on Jun 12, 2016 11:25:20 GMT -5
Agree, when scripts start rising everything will change including the stock price. While I believe scripts will rise, what if they only hit the highest mark while under Sanofi? The biggest question is how effective will the new sales team be in getting endos to prescribe? And remember, it appears the target as of right now is T1s and not T2s unless those endos seeing T2s change their protocol and start their T2s on Afrezza instead of metformin. Simply put MNKD most likely goes under. MNKD is marketing and commercializing under their own terms so if they can't get it right then Afrezza at this point in time isn't meant to be.
|
|
|
Post by mnkdfann on Jun 12, 2016 11:27:01 GMT -5
I wasn't talking about "eye candy" ... just regular happy Afrezza users telling their stories. Something very simple, cheap, and effective. Besides which, they don't have the money to get Miley Cyrus or any like celebrity involved in the marketing. The FDA has strict guidelines of what you can proclaim and what you can't. Doing what you have suggested would have run afoul of those guidelines. Mannkind can't parade their users around detailing their experience. The company would have to run a P4 clinical trial to prove lower A1c or anything else we have witnessed from users. Obviously, that takes moneyt hat Mannkind doesn't currently have. Worst case, they could have just included pictures of happy Afrezza users to fill in the blank spaces. Maybe with a few quotes just stating they liked Afrezza, found it easy to use, did not miss needles, etc. But no claims about effectiveness.
|
|
|
Post by cm5 on Jun 12, 2016 12:15:06 GMT -5
|
|